CHMP’s February 2024 Meeting: New Drug Recommendations

By Danélia Botes

February 24, 2024


The Committee for Medicinal Products for Human Use (CHMP) held its February 2024 meeting with numerous noteworthy outcomes. CHMP assessments are based on extensive scientific data analysis. They assess innovative drugs quality, safety, efficacy, and risk-benefit ratio. Internal peer-review ensures committee opinions are accurate and valid. In this article we highlight the key takeaways and their outcomes.

Ten New Medicines for Approval

The CHMP meeting saw the recommendation of ten new innovative medicines for approval. Two of these were vaccines aimed at active immunisation against the H5N1 subtype of influenza A virus, more commonly known as avian influenza or bird flu. The vaccines, Celldemic and Incellipan, are designed for immunisation during outbreaks of influenza from animals, including potential pandemics.

Innovations in Disease Treatment

Other significant recommendations included Filspari for the treatment of primary immunoglobulin A nephropathy, a disease where the kidneys gradually cease functioning, and Qalsody, a new therapy for treating adult patients with amyotrophic lateral sclerosis (ALS), a rare and often fatal disease, causing muscle weakness and leading to paralysis.

Advancements in Cancer and Blood Treatment

The meeting also saw positive opinions in the oncology and haematology landscape, including a recommendation for Tizveni, a treatment for locally advanced or metastatic non-small cell lung cancer, and Zynyz, a treatment for Merkel cell carcinoma, a life-threatening skin cancer with poor outcomes with advanced disease. Furthermore, the CHMP endorsed Voydeya, the first oral treatment for residual haemolytic anaemia in patients with paroxysmal nocturnal haemoglobinuria, a rare genetic disorder that causes the immune system to prematurely break down red blood cells. Voydeya was classified as an orphan drug during its development phase.

Biosimilar and Generic Medicines Approved

The CHMP meeting also saw the approval of Pyzchiva, an ustekinumab biosimilar intended for the treatment of plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease. In addition, two generic medicines received a positive opinion from the committee: Apremilast Accord for the use in the treatment of psoriatic arthritis, psoriasis and Behçet’s disease and also Nintedanib Accord for adults with idiopathic pulmonary fibrosis, other chronic fibrosing interstitial lung diseases with a progressive phenotype, and systemic sclerosis associated interstitial lung disease.

Extensions of Therapeutic Indication

The CHMP meeting recommended extensions of indication for six medicines already authorised in the European Union, including Carvykti, Cibinqo, Kalydeco, Keytruda, Reblozyl, and Xromi. The applicants for Nezglyal (also initially an orphan drug) and Syfovre requested the January 2024 committee’s opinions reexamined, and final recommendations will be provided.


The outcomes of the CHMP February 2024 meeting highlight the importance of a well-defined peer-review committee in the healthcare sector in order to evaluate and recommend new and innovative medicines. By ensuring an evidence-based process the CMHP strives to provide high level recommendations and allows for a thriving healthcare system which provides ample opportunity for innovation.

Reference url

Recent Posts

African Medicines Agency development

The African Medicine Agency’s Role in Advancing Healthcare

🌍 The #AfricanMedicinesAgency is set to change the face of healthcare in Africa. With a mission to provide quality, safe, and effective medical products, the AMA is a beacon of hope for enhanced health access. 🏥✨ #HealthcareInnovation #GlobalHealth #HealthForAll 💡

🔍 Discover how the AMA’s development is a crucial step towards a healthier continent. 🌐 #AMAdevelopment #AfricanUnion #HealthcareAccess🤝

. 📢 Read our latest article to understand the AMA’s vision, challenges, and the road ahead. Let’s unite for #HealthcareExcellence in Africa! 🌟

Economic Analysis in Clinical Trials

Economics in Clinical Trials: A Guide to Value-Based Decisions

🔬📚 We’ve just published an insightful piece on the importance of economic analysis in clinical trials 💊. It’s not just about proving efficacy, but also about understanding the value💰that new treatments bring to the table.

In a world where value-based healthcare is becoming the norm, this kind of analysis is absolutely essential for informed decision-making. Dive into the article to learn more about the role of economic endpoints, trial design, and types of economic analysis in clinical trials.

Join the discussion and share your thoughts! #ClinicalTrials #EconomicAnalysis #HealthcareEconomics #ValueBasedCare 🌐👩‍⚕️👨‍⚕️

AI in Healthcare Risk Adjustment

The Influence of AI on Risk Adjustment Models in Healthcare

🚀 #HealthcareInnovation Alert! Our latest update reveals a groundbreaking ML algorithm transforming risk adjustment models. 🧬💡

🔍 With enhanced predictive accuracy & fairness, we’re paving the way for smarter, more efficient healthcare resource allocation. 💊💰

👨‍⚕️👩‍⚕️ Clinicians, #LifeSciencesExperts, and #HealthcareProfessionals, discover how this innovation could change the game for patient care and financial planning. 📈

📖 Read our full article and join the conversation! ➡️

#ArtificialIntelligence #MachineLearning #HealthcareData #RiskAdjustment #AIinHealthcare #ValueBasedHealthcare

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.



1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA



© 2024 Syenza™. All rights reserved.